Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude Cardiovascular Access Sales Jump 107% In Q1 To $23 Mil.

This article was originally published in The Gray Sheet

Executive Summary

Strong U.S. sales of the 6 Fr version of St. Jude Medical's Angio-Seal hemostatic puncture closure system since its introduction in mid-March, and "the expansion and focus of cardiology vascular access selling efforts in the U.S.," were the driving forces behind a 107% jump in first quarter cardiovascular access product sales to $23 mil.

You may also be interested in...



Wall Street Apostles Find Salvation In St. Jude During 2Q; Stock Is Up 78%

A continued strong performance by St. Jude Medical's Cardiac Rhythm Management business combined with the expectation of key regulatory approvals by year-end sparked a 77.7% run-up in the company's stock during the second quarter of 2000.

Wall Street Apostles Find Salvation In St. Jude During 2Q; Stock Is Up 78%

A continued strong performance by St. Jude Medical's Cardiac Rhythm Management business combined with the expectation of key regulatory approvals by year-end sparked a 77.7% run-up in the company's stock during the second quarter of 2000.

St. Jude's AVERT Trial Data Induce Recall Of Silzone-Coated Heart Valve

St. Jude Medical's clinical study of the Regent mechanical heart valve henceforth will use only the non Silzone-coated version of the device, following the Jan. 24 recall of all products incorporating the proprietary antimicrobial coating, the firm says.

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel